{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:54:30Z","timestamp":1776250470833,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04683-2","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:53:37Z","timestamp":1772880817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term outcomes of aflibercept biosimilar SB15 in macular edema secondary to retinal vein occlusion"],"prefix":"10.1186","volume":"26","author":[{"given":"Jaejin","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"4683_CR1","first-page":"546","volume":"6","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Mieler WF. Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusions. Asia Pac J Ophthalmol (Phila). 2017;6:546\u201353.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"4683_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.21561\/jor.2018.3.1.20","volume":"3","author":"HG Kang","year":"2018","unstructured":"Kang HG, Seo Y, Choi EY, et al. Predictive Factors for a Favorable Response to Intravitreal Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion. J Retina. 2018;3:20\u20135.","journal-title":"J Retina"},{"key":"4683_CR3","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","volume":"119","author":"D Boyer","year":"2012","unstructured":"Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024\u201332.","journal-title":"Ophthalmology"},{"key":"4683_CR4","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122:538\u201344.","journal-title":"Ophthalmology"},{"key":"4683_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s12325-015-0279-0","volume":"33","author":"L Adedokun","year":"2016","unstructured":"Adedokun L, Burke C. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective. Adv Ther. 2016;33:116\u201328.","journal-title":"Adv Ther"},{"key":"4683_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.survophthal.2024.03.009","volume":"69","author":"NM Bressler","year":"2024","unstructured":"Bressler NM, Kaiser PK, Do DV, et al. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review. Surv Ophthalmol. 2024;69:521\u201338.","journal-title":"Surv Ophthalmol"},{"key":"4683_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","volume":"141","author":"SJ Woo","year":"2023","unstructured":"Woo SJ, Bradvica M, Vajas A, et al. Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023;141:668\u201376.","journal-title":"JAMA Ophthalmol"},{"key":"4683_CR8","doi-asserted-by":"publisher","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939.","journal-title":"Semin Arthritis Rheum"},{"key":"4683_CR9","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/OPTH.S180393","volume":"12","author":"A Sharma","year":"2018","unstructured":"Sharma A, Reddy P, Kuppermann BD, et al. Biosimilars in ophthalmology: Is there a big change on the horizon? Clin Ophthalmol. 2018;12:2137\u201343.","journal-title":"Clin Ophthalmol"},{"key":"4683_CR10","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s40123-023-00715-y","volume":"12","author":"Y Yanagi","year":"2023","unstructured":"Yanagi Y, Takahashi K, Iida T, et al. Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan. Ophthalmol Ther. 2023;12:2005\u201321.","journal-title":"Ophthalmol Ther"},{"key":"4683_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3341\/jkos.2019.60.7.667","volume":"60","author":"J Yang","year":"2019","unstructured":"Yang J, Shin SJ, Suh JK, et al. Budget Impact Analysis of Anti-vascular Endothelial Growth Factor in Patients with Diabetic Macular Edema. J Korean Ophthalmol Soc. 2019;60:667\u201375.","journal-title":"J Korean Ophthalmol Soc"},{"key":"4683_CR12","doi-asserted-by":"crossref","unstructured":"Sharma A, Woo SJ, Lee CS et al. Aflibercept 2\u00a0mg biosimilars-will they lead the Anti-VEGF biosimilar world globally. Eye (Lond) 2025.","DOI":"10.1038\/s41433-025-03732-2"},{"key":"4683_CR13","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s40123-024-00977-0","volume":"13","author":"H Lee","year":"2024","unstructured":"Lee H, Huh J, Kim D, et al. Analytical Characterization for Similarity Assessment Between an Aflibercept Biosimilar SB15 and Reference Product (Eylea(\u00ae)). Ophthalmol Ther. 2024;13:2209\u201325.","journal-title":"Ophthalmol Ther"},{"key":"4683_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40123-020-00277-3","volume":"9","author":"S Sharma","year":"2020","unstructured":"Sharma S, Khan M, Chaturvedi AA, Multicenter. Retrospective Study (RE-ENACT 2) on Razumab\u2122 (World\u2019s First Biosimilar Ranibizumab) in Retinal Vein Occlusion. Ophthalmol Ther. 2020;9:625\u201339.","journal-title":"Ophthalmol Ther"},{"key":"4683_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3341\/jkos.2025.66.1.27","volume":"66","author":"D Shin","year":"2025","unstructured":"Shin D, Kim Y, Kim JH. Short-term Outcomes of Ranibizumab Biosimilar CKD-701 Treatment in Macular Edema Secondary to Retinal Vein Occlusion. J Korean Ophthalmol Soc. 2025;66:27\u201335.","journal-title":"J Korean Ophthalmol Soc"},{"key":"4683_CR16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.oret.2024.04.014","volume":"8","author":"S Alforja","year":"2024","unstructured":"Alforja S, Hunt A, Nguyen V, et al. Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness! Ophthalmol Retina. 2024;8:962\u201370.","journal-title":"Ophthalmol Retina"},{"key":"4683_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2147\/OPTH.S133594","volume":"11","author":"Y Sakanishi","year":"2017","unstructured":"Sakanishi Y, Usui-Ouchi A, Tamaki K, et al. Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab. Clin Ophthalmol. 2017;11:829\u201334.","journal-title":"Clin Ophthalmol"},{"key":"4683_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10792-017-0798-6","volume":"39","author":"F Pichi","year":"2019","unstructured":"Pichi F, Elbarky AM, Elhamaky TR. Outcome of treat and monitor regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. Int Ophthalmol. 2019;39:145\u201353.","journal-title":"Int Ophthalmol"},{"key":"4683_CR19","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00417-021-05150-y","volume":"259","author":"DG Park","year":"2021","unstructured":"Park DG, Jeong WJ, Park JM, et al. Prospective trial of treat-and-extend regimen with aflibercept for branch retinal vein occlusion: 1-year results of the PLATON trial. Graefes Arch Clin Exp Ophthalmol. 2021;259:2879\u201386.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4683_CR20","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1001\/jamaophthalmol.2019.3305","volume":"137","author":"P Hykin","year":"2019","unstructured":"Hykin P, Prevost AT, Vasconcelos JC, et al. Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial. JAMA Ophthalmol. 2019;137:1256\u201364.","journal-title":"JAMA Ophthalmol"},{"key":"4683_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00417-017-3613-1","volume":"255","author":"I Chatziralli","year":"2017","unstructured":"Chatziralli I, Theodossiadis G, Moschos MM, et al. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data. Graefes Arch Clin Exp Ophthalmol. 2017;255:1093\u2013100.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4683_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/aos.13802","volume":"97","author":"K Spooner","year":"2019","unstructured":"Spooner K, Hong T, Bahrami B, Chang A. A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept. Acta Ophthalmol. 2019;97:15\u201323.","journal-title":"Acta Ophthalmol"},{"key":"4683_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.oret.2017.05.017","volume":"2","author":"RN Khurana","year":"2018","unstructured":"Khurana RN, Chang LK, Bansal AS, et al. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study. Ophthalmol Retina. 2018;2:128\u201333.","journal-title":"Ophthalmol Retina"},{"key":"4683_CR24","doi-asserted-by":"publisher","first-page":"10162","DOI":"10.1038\/s41598-022-14386-5","volume":"12","author":"Y Mun","year":"2022","unstructured":"Mun Y, Park C, Lee DY, et al. Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology. Sci Rep. 2022;12:10162.","journal-title":"Sci Rep"},{"key":"4683_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/tvst.10.4.9","volume":"10","author":"T Eissing","year":"2021","unstructured":"Eissing T, Stewart MW, Qian CX, Rittenhouse KD. Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes. Transl Vis Sci Technol. 2021;10:9.","journal-title":"Transl Vis Sci Technol"},{"key":"4683_CR26","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"4683_CR27","doi-asserted-by":"crossref","unstructured":"Lee TH, Nam KY, Kim JY. Comparison of Pro Re Nata and Three Loading Injections of Intravitreal Bevacizumab for Macular Edema in Branch Retinal Vein Occlusion. Journal of Retina 2019;4:17\u201322.","DOI":"10.21561\/jor.2019.4.1.17"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04683-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:04:29Z","timestamp":1776247469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04683-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4683"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04683-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Kim\u2019s Eye Hospital and was conducted in accordance with the tenets of the Declaration of Helsinki. Due to the retrospective nature of this study, the need for an informed consent was waived off (Kim\u2019s Eye Hospital IRB, Seoul, South Korea).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was not obtained since no identifying information of the participants was presented in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jae Hui Kim has received lecture fees from Chong Kun Dang Pharm. Co., Ltd. The company had no role in the design, conduct, analysis, or reporting of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}